Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
Shaji Kumar, Simon J. Harrison, Michèle Cavo, Javier de la Rubia, Rakesh Popat, Cristina Gasparetto, Vânia Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Elizabeth A. Punnoose, Wan‐Jen Hong, Kevin J. Freise, Xiaoqing Yang, Anjla Sood, Muhammad Jalaluddin, Jeremy A. Ross, James E. Ward, Paulo Maciag, Philippe Moreau
Topics & Concepts
BortezomibDexamethasoneVenetoclaxMultiple myelomaPlaceboMedicineRefractory (planetary science)Internal medicineDouble blindOncologyDaratumumabLeukemiaAlternative medicinePhysicsChronic lymphocytic leukemiaPathologyAstrobiologyMultiple Myeloma Research and TreatmentsCell death mechanisms and regulationCancer Mechanisms and Therapy